Company intelligence / Profile preview

ExpressCells

Philadelphia, Pennsylvania, United Statesinsidescientific.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

ExpressCells creates custom gene-edited cell lines using proprietary CRISPR and FAST-HDR technologies to accelerate drug discovery and basic biological research. No clinical results as the company provides enabling technologies rather than therapeutics.[1][3][6]

Therapeutic areas: Other
Modalities: Gene editing technology (CRISPR-based)Plasmid-based genetic engineering (FAST-HDR plasmid technology)Cell line engineering (custom knock-in cell lines)
Industry: Non-Drug Biotech

Partnerships

Temple University School of Pharmacy (technology origin)

Beyond the preview

Go deeper on ExpressCells.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExpressCells.

Explore the full profile